Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-06-20
2006-06-20
Devi, S. (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S235100, C435S272000, C436S086000
Reexamination Certificate
active
07063949
ABSTRACT:
Novel bactericidal antibodies againstNeisseria meningitidisserogroup B (“MenB”) are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB orE. coliK1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB orE. coliK1 disease without the risk of evoking autoantibody.
REFERENCES:
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4727136 (1988-02-01), Jennings et al.
patent: 4970070 (1990-11-01), Raff
patent: 5576002 (1996-11-01), Jennings et al.
patent: 5683699 (1997-11-01), Jennings
patent: 5811102 (1998-09-01), Jennings et al.
patent: 5902586 (1999-05-01), Jennings et al.
patent: 5969130 (1999-10-01), Jennings et al.
patent: 6030619 (2000-02-01), Granoff et al.
patent: 6048527 (2000-04-01), Granoff et al.
patent: 6638513 (2003-10-01), Seid
patent: 0 1 45 359 (1985-06-01), None
patent: 0 504 202 (1992-09-01), None
patent: WO 90/06696 (1990-06-01), None
patent: WO 91/08772 (1991-06-01), None
patent: WO 96/14086 (1996-05-01), None
patent: WO98/08543 (1998-03-01), None
U.S. Appl. No. 10/121,456, filed Apr. 11, 2002, Granoff et al, Not published.
Ashton et al.,Microb. Patheogeneis6:455-458 (1989).
Ashton et al.,In: Neisseria 1990, Achtman M. (Ed.),Walter De Gruyter&Co. Berlinpp. 187-191 (1991).
Bartoloni et al.,Vaccine13(5):463-470 (1995).
Baumann et al.,Biochemistry32:4007-4013 (1993).
Bitter-Suermann et al.,Immunol. Res. pp. 225-237 (1987).
Bowie et al.,Science247:1306-1310, 1990.
Brisson et al., Helical Epitope of the Group B Meningococcal α(2-8)-Linked Sialic Acid Polysaccharide,Biochemistry31:4996-5004 (1992).
Burgess et al.,J. Cell Biol. 111:2129-2138, 1990.
Cross et al.,J. Infect. Dis. 147(1):68-76 (1983).
Devi et al.,FEMS Immunol. Med. Microbiol. 14:211-220 (1996).
Devi et al., In:Neisseria:Proc. Ninth Internet. Pathogenic Neisseria Conference FEMS Immunolog. Med. Microbiol. Evans et al. (Ed.),S.C.C., Englandpp. 427-429 (1994).
Dubois et al., A Monoclonal Antibody AgainstMeningococcusGroup B Polysaccharides Used to Immunocapture and Quantify Polysialylated NCAM in Tissues and Biological Fluids,Journal of Immunological Methods181:125-135 (1995).
Frasch, Carl E., Meningococcal Vaccines: Past, Present and Future,Meningococcal Disease245-283 (1995).
Frosch et al.,PNAS82:1194-1198 (1985).
Fusco et al., Preclinical Evaluation of a Novel Group B Meningococcal Conjugate Vaccine that Elicits Bactericidal Activity in Both Mice and Nonhuman Primates,The Journal of Infectious Disease175:364-372 (1997).
Granoff et al.,J. Immunology160:5028-5036 (1998).
Granoff et al., Antibody Responses to the Capsular Polysaccharide ofNeisseria MenignitidisSerogroup B in Patients With Meningococcal Disease,Clinical and Diagnostic Laboratory Immunology2(5):574-582 (1995).
Gregson et al.,Biochem. Soc. Transact. 13:p.462 (1985).
Hayrinen et al., Antibodies to Polysialic Acid and its N-Propyl Derivative: Binding Properties and Interaction with Human Embryonal Brain Glycopeptides,The Journal Of Infectious Diseases171:0001-0010 (1995).
Horwell, David C., The ‘Peptoid’ Approach to the Design of Non-Peptide, Small Molecule Agonist and Antagonists of Neuropeptides,TIBTech13(4):132-134 (1995).
Hurpin et al.,Hybridoma11(6):677-687 (1992).
Husmann et al.,J. Histochem. Cytochem. 38:209-215 (1990).
Jennings, Harold J., The Capsular Polysaccharide of Group BNeisseria Meningitidisas a Vehicle for Vaccine Development,Microbiol. Immunol. 10:151-165 (1989).
Jennings et al., Induction ofMeningococcalGroup B Polysaccharide-Specific IgG Antibodies in Mice by Using an N-Propionylated B Polysaccharide-Tetanus Toxoid Conjugate Vaccine,The J. Of Immunology137(5):1708-1713 (1986).
Jennings et al., N-Polysialic Group B Meningococcal Polysaccharide Mimic a Unique Epitope on Group BNeisseria meningitidis, J. Experimental Medicine165:1207-1211 (1987).
Jennings et al., Unique Intermolecular Bactericidal Epitope Involving the Homosialopolysaccharide Capsule on the Cell Surface of Group BNeisseria meningitidisandEscherichia coliK1,Journal of Immunology142(10):3585-3591 (1989).
Jennings et al., Immunochemistry of Groups A,B, and C Meningococcal Polysaccharide-Tetanus Toxoid Conjugates,The Journal of Immunology127(3):1011-1018 (1981).
Kabat et al.,J. Exp. Med. 164:642-654 (1986).
Klebert et al.,Biol. Chem. Hoppe Seyler374:993-1000 (1993).
Lazar et al.,Mol. Cellular Biol. 8:1247-1252, 1988.
Leinonen et al.,Infect. Immun. 38(3):1203-1207 (1982).
Lifely et al.,Immunology74:490-496 (1991).
Livingston et al.,J. Biol. Chem. 263:9443-9448 (1988).
Lommatzsch et al.,J. Bacteriol. 179:5465-5470 (1997).
Lucas et al., Functional Differences in Idiotypically Defined IgG1 Anti-Polysaccharide Antibodies Elicited by Vaccination withHaemophilus influenzaeType B Polysaccharide-Protein Conjugates,The Journal of Immunology154:4195-4202 (1995).
Mandrell et al., Complement-Mediated Bactericidal Activity of Human Antibodies in Poly W α2→8 N-Acetylneuraminic Acid, the Capsular Polysaccharide ofNeisseria meningitidisSerogroup B,The Journal of Infectious Diseases172:1279-1289 (1995).
Michon et al., Conformational Differences Between Linear α(2→8)-Linked Homosialooligosaccharides and the Epitope of the Group B Meningococcal Polysaccharide,Biochemistry26:8399-8405 (1987).
Moreno et al.,J. Gen. Microbiol. 129:2451-2456 (1983).
Pizza et al., Identification of vaccine candidates against serogroup B Meningococcus by whole-genome sequencing,Science287:1816-1820 (2000).
Pon et al.,J. Exp. Med. 185:1929-1938 (1997).
Poolman, Jan T., Development of a Meningococcal Vaccine,Infectious Agents and Disease4:13-28 (1995).
Raff et al.,J. Infect. Dis. 157(1):118-126 (1988).
Rougon et al.,J. Cell. Biol. 103:2429-2437 (1986).
Sato et al.,J. Biol. Chem. 270:18923-18928 (1995).
Sukkonen et al.,Microbial. Pathogenesis1:101-105 (1986).
Tettelin et al., Complete genome sequence ofNeisseria meningitidisserogroup B strain MC58,Science287:1809-1815 (2000).
Tome et al.,Acta Pathol. Jpn. 43:168-175 (1993).
Vaesen et al.,Biol. Chem. Hoppe. Seyler372:451-453 (1993).
Westerink et al., Development and Characterization of an Anti-Idiotype Antibody to the Capsular Polysaccharide ofNeisseria mengingitidisSerogroup C,Infection and Immunity56(5):1120-1127 (1988).
DataBase WPI., Novel Strain ofNeisseria meningitidisGroup Useful Produce Capsule Polysaccharide Protein Complex, Jan. 30, 1992.
Granoff Dan M.
Moe Gregory R.
Children's Hospital Medical Center of Northern California
Chiron Corporation
Devi S.
Fortune Nicole M.
Harbin Alisa A.
LandOfFree
Methods for isolating molecular mimetics of unique... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for isolating molecular mimetics of unique..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for isolating molecular mimetics of unique... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3695406